Last updated on May 2019

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry


Brief description of study

Post-marketing safety data on patients treated and untreated with eculizumab.

Detailed Study Description

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Clinical Study Identifier: NCT01522183

Find a site near you

Start Over

Georgetown University Hospital

Washington, WA United States
  Connect »

Arthur James Cancer Hospital

Columbus, OH United States
  Connect »

Nepean Hospital

Penrith, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

Hopital Erasme

Brussels, Belgium
  Connect »

UZ Brussels

Brussels, Belgium
  Connect »

UZA (Adult)

Edegem, Belgium
  Connect »

CHU Ste Justine

Montréal, QC Canada
  Connect »

CHU Angers

Angers, France
  Connect »

CHG Bayonne

Bayonne, France
  Connect »

CHU Clermont Ferrand

Clermont-Ferrand, France
  Connect »

CHU Dijon

Dijon, France
  Connect »

CHU Grenoble

Grenoble, France
  Connect »

Le Kremlin Bicetre Hospital

Le Kremlin-Bicêtre, France
  Connect »

CHU de Montpellier

Montpellier, France
  Connect »

CH Perpignan

Perpignan, France
  Connect »

CHU Rangueil

Toulouse, France
  Connect »

CH Valenciennes

Valenciennes, France
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

CHU Ste Justine

Montréal, QC Canada
  Connect »

Le Kremlin Bicetre Hospital

Le Kremlin-Bicêtre, France
  Connect »